{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:06:46Z","timestamp":1780463206727,"version":"3.54.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The goal was having the comparisons be direct when it came to seeing how much of a help the sodium-glucose co transporter - 2 inhibitors (SGTL2is) compared to the glucagon-like peptide-1 receptor agonists (GLP-1RAs) were in regard to how the liver enzymes performed within people having type 2 diabetes (T2D) along with nonalcoholic fatty liver disease (NAFLD), a condition characterized by excessive fat accumulation in the liver without alcohol overconsumption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 705 subjects with T2DM and NAFLD at time of first SGLT2is (n=381) or GLP-1RAs (n=324) enrolment in this multicentre posterior cohort study from 01\/2020-12\/2024. Baseline characteristics were made equivalent via PSM via a 1: 1 NN match and a 0. 2 SD match clamp. The main measurement was the difference in alanine amino transferase (\u0394ALT) and aspartate aminotransferase (\u0394AST) from the beginning and 6 months. And other result was about the change in metabolic parametres. The independent predictors of liver-enzyme change came from the multivariate linear regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After PSM, 243 well-matched pairs were successfully identified, with baseline characteristics acceptably balanced (standardized differences &amp;lt;0.2 for all covariates and &amp;lt;0.1 for most covariates). In the matched cohort, SGLT2is treatment was associated with significantly greater reductions in ALT (\u0394ALT: -10.55 \u00b1 12.66 vs. -7.28 \u00b1 15.34 U\/L, p=0.011) and AST (\u0394AST: -7.68 \u00b1 10.07 vs. -5.18 \u00b1 11.04 U\/L, p=0.010) compared to GLP-1RAs treatment. No significant differences were observed for changes in GGT, body weight, glycemic control, or lipid profiles between groups. Multivariable regression analysis revealed that SGLT2is treatment was independently associated with reductions in both ALT (\u03b2 = -3.34, p=0.009) and AST (\u03b2 = -2.32, p=0.016). Weight change was independently associated with AST reduction (\u03b2 = 0.22, p=0.016) but not with ALT reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SGLT2is were associated with greater ALT and AST reductions than GLP-1RAs in T2D patients with NAFLD, with ALT improvement independent of weight loss, suggesting potential direct hepatoprotective effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1865769","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:51:00Z","timestamp":1780462260000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of SGLT-2 inhibitors and GLP-1 receptor agonists on liver function in patients with non-alcoholic fatty liver disease and type 2 diabetes"],"prefix":"10.3389","volume":"17","author":[{"given":"Wancheng","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Quanjiao County People\u2019s Hospital","place":["Chuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhe","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Quanjiao County People\u2019s Hospital","place":["Chuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianlin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Quanjiao County People\u2019s Hospital","place":["Chuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Huai 'an Clinical Medical College of Jiangsu University","place":["Huaian, China"]},{"name":"Department of Endocrinology, Huai 'an Hospital of Huai 'an City","place":["Huaian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Huai 'an Clinical Medical College of Jiangsu University","place":["Huaian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Huai 'an Clinical Medical College of Jiangsu University","place":["Huaian, China"]},{"name":"Department of Endocrinology, Huai 'an Hospital of Huai 'an City","place":["Huaian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Huai 'an Clinical Medical College of Jiangsu University","place":["Huaian, China"]},{"name":"Department of Endocrinology, Huai 'an Hospital of Huai 'an City","place":["Huaian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Huai 'an Clinical Medical College of Jiangsu University","place":["Huaian, China"]},{"name":"Department of Endocrinology, Huai 'an Hospital of Huai 'an City","place":["Huaian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3920196","article-title":"The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)","volume":"2020","author":"Tanase","year":"2020","journal-title":"J Diabetes Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076388","article-title":"Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study","volume":"384","author":"Kim","year":"2024","journal-title":"Bmj"},{"key":"B4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals","volume":"70","author":"Mantovani","year":"2021","journal-title":"Gut"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and Malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2016.06.005","article-title":"American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD)","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)00803-x","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1754721","article-title":"The mechanisms of GLP-1 receptor agonists in liver diseases: their multifaceted impact on immune response and metabolic regulation","volume":"17","author":"Hu","year":"2026","journal-title":"Front Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1210\/endrev\/bnac018","article-title":"Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease","volume":"44","author":"Yabut","year":"2023","journal-title":"Endocr Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3803\/enm.2025.2786","article-title":"SGLT2 inhibitors as systemic metabolic modulators: linking glucose excretion to liver function restoration","volume":"40","author":"Noh","year":"2025","journal-title":"Endocrinol Metab (Seoul)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-332687","article-title":"Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease","volume":"74","author":"Bea","year":"2025","journal-title":"Gut"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101661","article-title":"Impact of SGLT2i and GLP-1RA on liver-related events in patients with MASLD and type 2 diabetes: a network meta-analysis","volume":"8","author":"Li","year":"2026","journal-title":"JHEP Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"key":"B20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/ajg.2016.517","article-title":"ACG clinical guideline: evaluation of abnormal liver chemistries","volume":"112","author":"Kwo","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1055\/a-2787-1205","article-title":"Exploring the therapeutic potential of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis in patients with type 2 diabetes: a narrative review","volume":"58","author":"Al Rashid","year":"2026","journal-title":"Horm Metab Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ebiom.2018.01.008","article-title":"AMPK re-activation suppresses hepatic steatosis but its downregulation does not promote fatty liver development","volume":"28","author":"Boudaba","year":"2018","journal-title":"EBioMedicine"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.589273","article-title":"Dapagliflozin alleviates hepatic steatosis by restoring autophagy via the AMPK-mTOR pathway","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.10.030","article-title":"Hyperuricemia and gout reduction by SGLT2 inhibitors in diabetes and heart failure: JACC review topic of the week","volume":"83","author":"Packer","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.11.022","article-title":"Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism","volume":"64","author":"Wan","year":"2016","journal-title":"J Hepatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101411","article-title":"URAT1-selective inhibition ameliorates insulin resistance by attenuating diet-induced hepatic steatosis and brown adipose tissue whitening in mice","volume":"55","author":"Tanaka","year":"2022","journal-title":"Mol Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(22)00338-7","article-title":"Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease","volume":"8","author":"Targher","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1177\/10600280251322002","article-title":"Therapeutic potential of GLP-1 receptor agonists in metabolic associated steatotic liver disease","volume":"59","author":"Nowak","year":"2025","journal-title":"Ann Pharmacother"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives","volume":"24","author":"Nevola","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(18)30024-x","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12841","article-title":"Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: mechanistic possibilities","volume":"20","author":"Brown","year":"2019","journal-title":"Obes Rev"},{"key":"B32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/978-3-030-36694-0_17","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/818570","article-title":"Gamma-glutamyltransferase: a predictive biomarker of cellular antioxidant inadequacy and disease risk","volume":"2015","author":"Koenig","year":"2015","journal-title":"Dis Markers"},{"key":"B34","first-page":"102","article-title":"Clinicopathological evaluation of Moyamoya disease. Case report and review of literature","volume":"123","author":"Pop","year":"2020","journal-title":"Rom J Mil Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3171\/2025.12.jns251072","article-title":"Glucagon-like peptide-1 receptor agonists in patients with moyamoya disease and type 2 diabetes mellitus","author":"Roy","year":"2026","journal-title":"J Neurosurg"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2019.12.006","article-title":"SGLT2 inhibitor-induced euglycemic diabetic ketoacidosis: a case report","volume":"2","author":"Wang","year":"2020","journal-title":"Kidney Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1865769\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:51:08Z","timestamp":1780462268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1865769\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":36,"alternative-id":["10.3389\/fendo.2026.1865769"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1865769","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"article-number":"1865769"}}